Igenica
Burlingame
About Igenica
Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. They are the only biotherapeutic company that fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, accelerating development and the delivery of effective therapies to patients. Founded in 2009, Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. Their leadership team has played a seminal role in six out of the 36 currently approved antibody therapeutic products. Based in Burlingame, Calif., they are well-funded by a premier team of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $80.6M
- Last round: Series Unknown (Jun 2015)
- Website: igenica.com
- Phone: 6506974900
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/igenica-814513 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.